Influence of Government Price Regulation on the Price, Volume and Spending of Antibiotics in China: A Controlled Interrupted Time Series Study

Document Type: Original Article

Authors

1 Center for Strategic Studies, Chinese Academy of Engineering, Beijing, China

2 School of Medicine, Tsinghua University, Beijing, China

3 International Research Center for Medicinal Administration (IRCMA), Peking University, Beijing, China

4 Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China

Abstract

Background
Chinese government established maximum retail prices for antibiotics listed in China’s National Reimbursement List in February 2013. This study aimed to analyze the impact of pharmaceutical price regulation on the price, volume and spending of antibiotics in China.

 
Methods
An interrupted time series design with comparison series was used to examine impacts of the policy changes on average daily cost, monthly hospital purchase volume and spending of the 11 price-regulated antibiotics and 40 priceunregulated antibiotics in 699 hospitals. One intervention point was applied to assess the impact of policy.

 
Results
After government price regulation, compared to price-unregulated antibiotics, the average daily cost of the price-regulated group declined rapidly (β = -5.68, P < .001). The average hospital monthly purchase spending of priceregulated antibiotics also decreased rapidly (β = -0.49, P < .010) and a positive trend change (β = 0.04, P < .001) in average hospital spending of price-unregulated antibiotics was found.

 
Conclusion
Government regulation can reduce the prices and spending of price-regulated antibiotics. To control increasing expenditure, besides price caps regulation, factors determining drug utilization also need to be considered in policy designing.

Highlights

 

Supplementary File 1 (Download)

 

Keywords


  1. Belloni A, Morgan D, Paris V. Pharmaceutical Expenditure and Policies. Paris: OECD Publishing; 2016. doi:10.1787/5jm0q1f4cdq7-en
  2. OECD. Pharmaceutical Expenditure. OECD; 2010:132-133.
  3. Ess SM, Schneeweiss S, Szucs TD. European healthcare policies for controlling drug expenditure. Pharmacoeconomics. 2003;21(2):89-103. doi:10.2165/00019053-200321020-00002
  4. Borrell JR. Drug price regulation: recent trends and downstream neglected issues. In: Garcia-Fontes WA, ed. Incentives for Research, Development, and Innovation in Pharmaceuticals. Madrid: Springer Healthcare; 2011:81-96. doi:10.1007/978-84-938062-7-9_7
  5. Sood N, de Vries H, Gutierrez I, Lakdawalla DN, Goldman DP. The effect of regulation on pharmaceutical revenues: experience in nineteen countries. Health Aff (Millwood). 2009;28(1):w125-137. doi:10.1377/hlthaff.28.1.w125
  6. Rane W. Price Control on Drugs Is Essential. Economic and Political Weekly. 1998;33(42):2697-2698.
  7. López-Casasnovas G, Puig-Junoy J. Review of the literature on reference pricing. Health Policy. 2000;54(2):87-123. doi:10.1016/s0168-8510(00)00100-7
  8. Brekke KR, Grasdal AL, Holmås TH. Regulation and pricing of pharmaceuticals: reference pricing or price cap regulation? Eur Econ Rev. 2009;53(2):170-185. doi:10.1016/j.euroecorev.2008.03.004 
  9. Stigler GJ. The theory of economic regulation. Bell J Econ Manage Sci. 1971;2(1):3-21. doi:10.2307/3003160
  10. Miziara NM, Coutinho DR. Problems in the regulatory policy of the drug market. Rev Saude Publica. 2015;49:35. doi:10.1590/s0034-8910.2015049005779
  11. Vaidyanathan G. Poor May Suffer as India Caps Drug Prices. Nature; 2012. https://www.nature.com/news/poor-may-suffer-as-india-caps-drug-prices-1.12046.  Accessed June 5, 2019.
  12. Sun Q, Santoro MA, Meng Q, Liu C, Eggleston K. Pharmaceutical policy in China. Health Aff (Millwood). 2008;27(4):1042-1050. doi:10.1377/hlthaff.27.4.1042
  13. World Bank. Fixing the Public Hospital System in China. Washington, DC: World Bank; 2010.
  14. National Development and Reform Commission. Notice on the Government Pricing Scheme for Medicines. http://zwgk.gd.gov.cn/006939828/201308/t20130830_399800.html.  Accessed June 5, 2019. Published 2003.
  15. Luk S. The politics of drug price control policy in China: regulation, deregulation and Re-regulation. J Contemp East Asia Stud. 2015;4(1):41-54. doi:10.1080/24761028.2015.11869080
  16. National Development and Reform Commission. List of Priced Drugs of the National Development and Reform Commission. http://www.ndrc.gov.cn/fzgggz/jggl/zcfg/200508/t20050802_747962.html.  Accessed March 25, 2019.
  17. Li Y, Xu J, Wang F, et al. Overprescribing in China, driven by financial incentives, results in very high use of antibiotics, injections, and corticosteroids. Health Aff (Millwood). 2012;31(5):1075-1082. doi:10.1377/hlthaff.2010.0965
  18. Guan X, Liang H, Xue Y, Shi L. An analysis of China's national essential medicines policy. J Public Health Policy. 2011;32(3):305-319. doi:10.1057/jphp.2011.34
  19. Han S, Liang H, Su W, Xue Y, Shi L. Can price controls reduce pharmaceutical expenses? a case study of antibacterial expenditures in 12 Chinese hospitals from 1996 to 2005. Int J Health Serv. 2013;43(1):91-103. doi:10.2190/HS.43.1.g
  20. National Development and Reform Commission. Notice on the Government Pricing Scheme for Immune system, Anti-cancer and Blood system Medicines.  http://www.ndrc.gov.cn/fzgggz/jggl/zcfg/201209/t20120918_505462.html.  Accessed September 6, 2019.
  21. Science and Technology Development Center of Chinese Pharmaceutical Association. Brief Introduction to CMEI.  http://www.cmei.org.cn/list/?343_1.html.  Accessed February 14, 2020.
  22. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC Classification and DDD Assignment. https://www.whocc.no/filearchive/publications/2019_guidelines_web.pdf.  Accessed July 23, 2019. Published 2019.
  23. Yearbook of Chinese Health Statistics in 2015. China Ministry of Health; 2016.
  24. Defined daily dose. Pharmacoecon. Outcomes News. 1995;29:6. doi:10.1007/BF03309626
  25. National Bureau of Statistics of China. Time Series Data -- Annual Data: The Exchange Rate Between RMB and USD. http://data.stats.gov.cn/english/easyquery.htm?cn=C01.  Accessed November 20, 2019.
  26. Meng Q, Cheng G, Silver L, Sun X, Rehnberg C, Tomson G. The impact of China's retail drug price control policy on hospital expenditures: a case study in two Shandong hospitals. Health Policy Plan. 2005;20(3):185-196. doi:10.1093/heapol/czi018
  27. Dong Z, Liu G, Wu J, Wu J. Effects of drug price control policies on antibiotics: evidence from Beijing. China Journal of Pharmaceutical Economics. 2008;3:7-12.
  28. Guan X, Wushouer H, Yang M, et al. Influence of government price regulation and deregulation on the price of antineoplastic medications in China: a controlled interrupted time series study. BMJ Open. 2019;9(11):e031658. doi:10.1136/bmjopen-2019-031658
  29. Yip WC, Hsiao W, Meng Q, Chen W, Sun X. Realignment of incentives for health-care providers in China. Lancet. 2010;375(9720):1120-1130. doi:10.1016/s0140-6736(10)60063-3
  30. China National Health Accounts Report. China National Health Development Research Center; 2009.
  31. Wushouer H, Tian Y, Guan XD, Han S, Shi LW. Trends and patterns of antibiotic consumption in China's tertiary hospitals: Based on a 5 year surveillance with sales records, 2011-2015. PLoS One. 2017;12(12):e0190314. doi:10.1371/journal.pone.0190314
  32. Wushouer H, Zhou Y, Zhang X, et al. Secular trend analysis of antibiotic utilisation in China's hospitals 2011-2018, a retrospective analysis of procurement data. Antimicrob Resist Infect Control. 2020;9(1):53. doi:10.1186/s13756-020-00709-6
  33. Department of Medical Administration and Committee of Experts on Rational Drug Use, National Health and Family Planning Commission of the People's Republic of China. National Antimicrobial Therapy Guidance. 1st ed. Beijing: People's Medical Publishing House Co Ltd; 2012.
  34. He P, Sun Q, Shi L, Meng Q. Rational use of antibiotics in the context of China's health system reform. BMJ. 2019;365:l4016. doi:10.1136/bmj.l4016
  35. Xiao Y, Li L. Legislation of clinical antibiotic use in China. Lancet Infect Dis. 2013;13(3):189-191. doi:10.1016/s1473-3099(13)70011-2
  36. Yin J, Li Q, Sun Q. Antibiotic consumption in Shandong Province, China: an analysis of provincial pharmaceutical centralized bidding procurement data at public healthcare institutions, 2012-16. J Antimicrob Chemother. 2018;73(3):814-820. doi:10.1093/jac/dkx469
  37. China Minister of Health. Regulations for clinical application of antibacterial agents (Decree No. 23 Issued by the Minister of Health). Chinese Journal of Clinical Infectious Diseases. 2012;05:193-196.
  38. Xiao Y. Antimicrobial stewardship in China: systems, actions and future strategies. Clin Infect Dis. 2018;67(suppl_2):S135-s141. doi:10.1093/cid/ciy641
  39. Yin J, Wu C, Wei X, Sun Q. Antibiotic expenditure by public healthcare institutions in Shandong province in China, 2012-2016. Front Pharmacol. 2018;9:1396. doi:10.3389/fphar.2018.01396